AIM ImmunoTech Stock Scheduled to Split on Friday, January 9th (NYSEAMERICAN:AIM)

AIM ImmunoTech Inc. (NYSEAMERICAN:AIM) shares are going to split on Friday, January 9th. The 1001-1000 split was recently announced. The newly created shares will be distributed to shareholders after the market closes on Thursday, January 8th.

AIM ImmunoTech Stock Performance

Shares of AIM opened at $1.19 on Monday. AIM ImmunoTech has a fifty-two week low of $1.07 and a fifty-two week high of $36.00. The company has a market capitalization of $3.39 million, a PE ratio of -0.06 and a beta of 1.21. The stock has a fifty day moving average of $1.53 and a two-hundred day moving average of $3.47.

AIM ImmunoTech (NYSEAMERICAN:AIM) last issued its quarterly earnings results on Monday, November 17th. The company reported ($1.57) earnings per share for the quarter. The business had revenue of $0.03 million during the quarter. As a group, equities research analysts forecast that AIM ImmunoTech will post -0.3 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Separately, Zacks Research lowered shares of AIM ImmunoTech from a “strong-buy” rating to a “hold” rating in a report on Monday, December 1st. One investment analyst has rated the stock with a Strong Buy rating and one has issued a Hold rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of “Buy”.

Hedge Funds Weigh In On AIM ImmunoTech

A hedge fund recently bought a new stake in AIM ImmunoTech stock. Corient Private Wealth LLC bought a new stake in shares of AIM ImmunoTech Inc. (NYSEAMERICAN:AIM) during the 2nd quarter, according to the company in its most recent 13F filing with the SEC. The fund bought 10,001 shares of the company’s stock, valued at approximately $87,000. Corient Private Wealth LLC owned approximately 0.37% of AIM ImmunoTech at the end of the most recent quarter. 12.02% of the stock is currently owned by institutional investors and hedge funds.

About AIM ImmunoTech

AIM ImmunoTech is a clinical-stage biotechnology company focused on the development and commercialization of immune-modulating therapies for the treatment of viral infections and cancer. The company’s lead product candidate, Ampligen (rintatolimod), is a proprietary toll-like receptor 3 (TLR3) agonist that aims to enhance the body’s innate immune response. AIM ImmunoTech’s research and development efforts center on demonstrating the safety and efficacy of Ampligen as both a standalone therapy and in combination with other treatments.

In addition to its oncology and antiviral programs, the company is advancing clinical trials of Ampligen in patients with chronic fatigue syndrome/myalgic encephalomyelitis (CFS/ME) and exploring potential applications for emerging viral threats.